MedNet.nl: Large cardiovascular outcome studies have shown cardiovascular benefits of SGLT2 inhibitors (SGLT2i) and GLP1 receptor agonists (GLP-1 RA) in people with type 2 diabetes. Both classes of drugs also lower the 5-year risk of microvascular complications, according to a retrospective cohort analysis of 6 million people with type 2 diabetes.
10-10-2023 | Type 2 Diabetes | News
EASD 2023